Enanta Pharma (ENTA) Tops Q2 EPS by 8c

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of $0.61, $0.08 better than the analyst estimate of $0.53. Revenue for the quarter came in at $44.05 million versus the consensus estimate of $40.77 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• VNET Group (VNET) Misses Q2 EPS by 164c
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Alpha Cognition Inc (ACOG) PT Raised to $20 at H.C. Wainwright